anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Preparations to be dissolved to produce anaesthetic solutions for injection comprise a salt of an anaesthetic base, a vaso-constricting agent, a buffer substance giving a pH of about 7 and a water soluble reducing agent, mixed together in dry condition and again thoroughly dried after admixture.  The mixtures may be put up in the form of tablets.  Inert salts such as sodium chloride, sodium sulphate, potassium sulphate, or mixtures thereof, may be added so that on solution in water the preparations are isotonic with the body fluids. Water-binding salts, such as calcined sodium sulphate may also be added. Suitable anaesthetic salts are the hydrochloride or sulphate of p-amino-benzoic acid-diethyl-amino-ethyl ester and salts of various specified related compounds; vaso-constrictors are the bitartrate or hydrochloride of o-dihydroxy-phenyl-ethanol-methylamine, and p-hydroxy-phenyl-methyl aminoethanol; buffers are disodium phosphate, sodium bicarbonate, sodium borate, or a small quantity of the free an sthetic base or of its salt with boric or other feeble acid; reducing agents are sodium and potassium sulphites, sodium bisulphite, formaldehyde bisulphite, acetone bisulphite, sodium hyposulphate, formaldehyde sulphoxylate, alkali metal salts of phosphorous or hypophosphorous acids, or mixtures of these.  Numerical examples are given.
The invention provides an application device and a container used for applying a solution on an eyelid for form a double eyelid. The invention includes an eyelid application tool and an eyelid application solution in the container. The solution is composed of a solvent and a substrate. The solvent is ethyl alcohol accounting for above 75 mass% in the solution. The substrate is soluble in the solution. When the solution is applied to the eyelid, successive-curve form, over an imaginary line is formed a fold of a double eyelid in the eyelid onto which a user want to make a fold and vaporizing the solvent so as to shrink the film. The substrate is made of fiber-shaped material shrunk along with the vaporization of the solvent. The fiber-shaped solvent is cellulose nitrate and the content in the solution is 5 mass% to 25 mass%. The film shrinks along with the shrinking of fiber-shaped material and attaches to the skin of the eyelid.
There is described a scaffold for repair of cartilage or an osteochondral defect. The scaffold comprises coral having at least a first portion of an exposed surface. The first portion is raised with respect to at least a second portion of the exposed surface in the coral. The at least a first portion of the coral is proximal to a hollow or hollows along a longitudinal axis of the first portion and the at least a second portion abuts the hollow or hollows. The first portion comprises at least a region, which specifically positions and confines the coral within a site of cartilage repair. This invention provides the unexpected application of coral scaffolding alone being useful in cartilage repair and moreover, that coral scaffolding can be prepared and inserted specifically and optimally within a site of cartilage repair for methods of cartilage repair.
PURPOSE:To obtain a water-based manicure free from the health hazard caused by the inhalation of organic solvent and the deterioration of nail and giving a resin coating film removable even with water or a uniform mixture of water and organic solvent by using a water-based polyurethane under specific condition. CONSTITUTION:The objective agent contains a polyurethane having a neutralization number of 10-80 and produced by polymerizing in the absence of tertiary amine. The polyurethane is produced in the form of an aqueous dispersion having a solid content of 5-60wt.%. A manicure giving a dried resin coating film removable with water or a uniform mixture of water and an organic solvent (e.g. acetone or ethanol) can be produced by using the polyurethane in an amount of 3-100wt.% in terms of solid. The coating film has excellent adhesivity to the nail and high gloss and hardness.
<P>PROBLEM TO BE SOLVED: To provide a method for forming, caring and re-removing temporary Rasta hair style (Rasta-Frisuren).  <P>SOLUTION: This method comprises one or more of the following processes: a process of applying a substance for increasing the roughness of the surface of hair on the hair, a process of applying a substance for increasing the adhesion of the hair each other on the hair, and a process of forming temporary Rasta hair bundles by combing the hair as the state of hair bundles. The cleaning of such Rasta hair style is preferably performed by using a recess-surfaced sponge so as not to destroy the hair style. To re-remove the temporary Rasta hair style, a preparation for increasing the wet comb-passing property is applied on the hair to release and loosen the Rasta hair bundles. A kit consisting of multiple components for performing such method is also provided.  <P>COPYRIGHT: (C)2004,JPO
Participants will be asked to take the Dynamic AFO home and wear the device for up to 4 weeks. The device will be set in either an adjustment-capable mode, or a "locked" mode that functions similar to their own orthotic--the order in which they are tested will be randomized.
AIMS: The aim of this study was to compare the biomechanical models of two frequently used techniques for reconstructing severe acetabular defects with pelvic discontinuity in revision total hip arthroplasty (THA) - the Trabecular Metal Acetabular Revision System (TMARS) and custom triflange acetabular components (CTACs) - using virtual modelling.
METHODS: Pre- and postoperative CT scans from ten patients who underwent revision with the TMARS for a Paprosky IIIB acetabular defect with pelvic discontinuity were retrospectively collated. Computer models of a CTAC implant were designed from the preoperative CT scans of these patients. Computer models of the TMARS reconstruction were segmented from postoperative CT scans using a semi-automated method. The amount of bone removed, the implant-bone apposition that was achieved, and the restoration of the centre of rotation of the hip were compared between all the actual TMARS and the virtual CTAC implants.
RESULTS: The median amount of bone removed for TMARS reconstructions was significantly greater than for CTAC implants (9.07 cm3 (interquartile range (IQR) 5.86 to 21.42) vs 1.16 cm3 (IQR 0.42 to 3.53) (p = 0.004). There was no significant difference between the median overall implant-bone apposition between TMARS reconstructions and CTAC implants (54.8 cm2 (IQR 28.2 to 82.3) vs 56.6 cm2 (IQR 40.6 to 69.7) (p = 0.683). However, there was significantly more implant-bone apposition within the residual acetabulum (45.2 cm2 (IQR 28.2 to 72.4) vs 25.5 cm2 (IQR 12.8 to 44.1) (p = 0.001) and conversely significantly less apposition with the outer cortex of the pelvis for TMARS implants compared with CTAC reconstructions (0 cm2 (IQR 0 to 13.1) vs 23.2 cm2 (IQR 16.4 to 30.6) (p = 0.009). The mean centre of rotation of the hip of TMARS reconstructions differed by a mean of 11.1 mm (3 to 28) compared with CTAC implants.
CONCLUSION: In using TMARS, more bone is removed, thus achieving more implant-bone apposition within the residual acetabular bone. In CTAC implants, the amount of bone removed is minimal, while the implant-bone apposition is more evenly distributed between the residual acetabulum and the outer cortex of the pelvis. The differences suggest that these implants used to treat pelvic discontinuity might achieve short- and long-term stability through different biomechanical mechanisms.
BACKGROUND: Interleukin (IL)-38, the latest member of the IL-1 cytokine family, is proposed to have a pathogenic role in rheumatoid arthritis (RA). It is encoded by the IL1F10 gene, which harbors single nucleotide polymorphisms (SNPs) that may predict the risk of autoimmune diseases. Among them are 5' untranslated region (UTR) SNPs, which play a key role in post-transcriptional control, but have not been studied in Iraqi RA patients.
METHODS: Two novel IL1F10 5'UTR SNPs (rs3811050 C/T and rs3811051 T/G) were explored in RA and control women (n = 120 and 110, respectively). SNPs were genotyped using TaqMan assay. An ELISA kit was used to measure serum IL-38 concentrations.
RESULTS: A reduced risk of RA was associated with rs3811050 T allele and CT genotype (corrected probability [pc] = 0.01 and < 0.001, respectively), while there was no significant association with rs3811051. Haplotype analysis demonstrated that C-T haplotype was associated with a 1.65-fold greater risk of RA, whereas a reduced risk was linked to T-G haplotype. IL-38 concentrations were higher in patients than in controls (p < 0.001). In addition, IL-38 showed acceptable performance in distinguishing between RA and control women (p < 0.001). When IL-38 concentrations were stratified according to SNP genotypes, no significant differences were found.
CONCLUSIONS: The rs3811050 variant was more likely to affect RA susceptibility in Iraqi women, and the T allele may play a role in reducing disease risk. IL-38 concentrations were elevated in RA patients, but were not affected by the rs3811050 and rs3811051 genotypes.
Deaf and hard of hearing (DHH) children are developmentally delayed in facial emotion recognition (FER). This study aimed to explore the possibility of enhancing the FER ability of DHH preschoolers through a group-play intervention. Nineteen children with a cochlear implant or hearing aid were enrolled in a 4-week intervention; six DHH children were assigned to a control group. The training program included a learning procedure for four basic emotions: happiness, sadness, anger, and fear. A pretest/posttest design was used to measure the DHH children's FER performance. The results indicated that although the two groups performed comparably on the FER task before the training (pretest), the performance of the intervention group was significantly better than that of the control group in the posttest. Moreover, the DHH children in the intervention group showed the greatest improvement in FER of happiness.
A good death is a human right. Unfortunately, patients with chronic heart failure (CHF) in the terminal stage still receive inappropriate life-sustaining treatment before death. There is limited understanding of the status of intensive care unit (ICU) admission, mechanical ventilation (MV), cardiopulmonary resuscitation (CPR), and even extracorporeal membrane oxygenation (ECMO) for patients with CHF before death, as well as their use of hospice-related services. This study investigated the trends and trend changes in intensive procedures and hospice-related services for patients with CHF in the last month of life. This population-based retrospective observational study included 25 375 patients with CHF from the National Health Insurance research database in Taiwan and collected information on their intensive treatments during the last month of life. We computed intensive treatment utilization rates and analyzed the trends and trend changes via joinpoint regression. The average percentage of patients with CHF admitted to ICUs was 53.27% (n = 13 516). A total of 327 (1.29%) patients with CHF received ECMO. The percentages of patients receiving MV (54.3%'41.5%) and CPR (41.5%'17%) decreased over time. Conversely, the percentage of ECMO use (0.52%'1.78%) increased. However, only 222 (0.87%) patients with CHF received hospice care in the last month of life between 2001 and 2013. The rates of ICU admission and life-sustaining treatment among patients with CHF in the month before death remain high, and hospice-related services remain inadequate. This study highlights the need for research and training in providing palliative and hospice care for patients with CHF.
The goal of this observational study is to collect clinical and abdominal imaging data of patients with liver cirrhosis. The collected imaging data will be used as a model development set to develop, test, and internally validate a fully automated imaging deep learning platform for the evaluation of sarcopenia in liver cirrhosis. Subsequently, relevant data from patients with liver cirrhosis at other centers will be collected and used as an external validation dataset. The model will be externally validated by abdominal radiology experts. Furthermore, we will include sociodemographic information, clinical data, imaging data, and clinical outcomes of the aforementioned liver cirrhosis patients to predict the prognosis of these patients using the established model. This model will be used to construct a new prognostic model for liver cirrhosis incorporating imaging biomarkers such as sarcopenia, and its predictive performance will be validated.
Several large cohort studies in cardiovascular disease (CVD) patients have shown an increased incidence of cancer. Previous studies in a myocardial infarction (MI) mouse model reported increased colon, breast, and lung cancer growth. The potential mechanisms could be due to secreted cardiokines and micro-RNAs from pathological hearts and immune cell reprogramming. A study in a MI-induced heart failure (HF) mouse demonstrated an increase in cardiac expression of SerpinA3, resulting in an enhanced proliferation of colon cancer cells. In MI-induced HF mice with lung cancer, the attenuation of tumor sensitivity to ferroptosis via the secretion of miR-22-3p from cardiomyocytes was demonstrated. In MI mice with breast cancer, immune cell reprogramming toward the immunosuppressive state was shown. However, a study in mice with renal cancer reported no impact of MI on tumor growth. In addition to MI, cardiac hypertrophy was shown to promote the growth of breast and lung cancer. The cardiokine potentially involved, periostin, was increased in the cardiac tissue and serum of a cardiac hypertrophy model, and was reported to increase breast cancer cell proliferation. Since the concept that CVD could influence the initiation and progression of several types of cancer is quite new and challenging regarding future therapeutic and preventive strategies, further studies are needed to elucidate the potential underlying mechanisms which will enable more effective risk stratification and development of potential therapeutic interventions to prevent cancer in CVD patients.
PURPOSE: Provided is a composition comprising extracts of Cucumis melon Linn. var. ma-gua, Lxeris dentata and Youngia sonchifolia for the treatment of chronic viral hepatitis diseases. It increases liver function, inhibits HBV DNA proliferation to show antiviral effect, and is thus useful for prevention and treatment of chronic viral hepatitis diseases. CONSTITUTION: A pharmaceutical composition for prevention and treatment of chronic viral hepatitis diseases is characterized by containing, based on the total weight of the composition, 0.5-50% of crude extracts of Cucumis melon Linn. var. ma-gua, Lxeris dentata and Youngia sonchifolia having effective inhibition effect on HBV DNA proliferation. The crude extract is obtained by using a polar solvent selected from water, methanol, ethanol, a mixture thereof, and a buffer solution.
<P>PROBLEM TO BE SOLVED: To provide a method of inducing an immune response expressing a heterologous immunogen by generating an attenuated vaccine from a Venezuelan Equine Encephalitis (VEE) virus.  <P>SOLUTION: A method of protecting a subject against a disease comprises administering a recombinant VEE virus to the subject in an effective immunogenic amount. The VEE virus contains a heterologous DNA segment, and the heterologous DNA segment comprises a promoter operable in the subject operatively associated with a DNA encoding an immunogenic protein or peptide effective for protecting the subject from the disease. Preferred promoters are VEE 26S subgenomic promoters, and preferred immunogens are viral immunogens. Novel attenuating mutations useful in carrying out the invention are also disclosed.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Intravitreal injections of 0.5mg Ranibizumab at baseline and at 4 weeks. Focal/grid laser for diabetic macular edema was performed 3 days to 10 days after the injection for all treatment groups.
Children will receive a reformulated RUTF, with increased medium-chain triglycerides (MCTs), higher hydrolysed protein content and a more bioavailable form of selenium (selenium yeast). Children will receive RUTF for at least 2 weeks.
The tools currently employed to assess skeletal muscle mass (SMM), including DXA, have substantial drawbacks. DXA does not measure muscle per se but provides an assessment of lean soft tissue (LST) as a proxy for skeletal muscle. Even if confined to the appendages (aLST), DXA assessments include many non-muscle constituents (e.g., connective tissue, water), which are poorly and inconsistently related to mobility and falls with aging. As a superior measure to DXA, the investigators will use a novel, stable isotope-labelled probe to measure SMM. This method uses the oral ingestion of a small dose of deuterium (D)-labelled creatine (D3-creatine; D3-Cr), which is irreversibly converted to creatinine when taken up by skeletal muscle. The dilution of the labelled creatinine provides a safe, non-invasive, and highly accurate measure of SMM. The utilization of D3-Cr-measured SMM (D3-Cr-SMM) requires no specific diet and requires only the collection of a spot urine sample.

The plan is to recruit a sub-sample of older Canadians between 60 and 80 living in the greater Hamilton-Toronto area. Participants will be recruited through the MacM3 (M3) cohort study. MacM3 will enroll a sample of 2,000 participants from a pre-recruited representative sample of more than 10,000 older adults living in the greater Hamilton and Toronto areas who consented to be contacted for further research as part of a larger research platform. From this pool of 2000 individuals in MacM3, the plan is to recruit 350 people. Participants will be classified across the three levels of mobility limitations based on the MacM3 screening criteria of preclinical mobility limitation (i.e., able to manage without difficulty - no mobility limitation, able to manage without difficulty but sometimes with task modification - early mobility limitation, and able to manage with minor difficulty - minor mobility limitation, which will provide valuable insight into whether changes in D3-Cr-SMM are associated with a change in categorical mobility status.

The proposed research design is a prospective cohort study including 350 older (65-80 y) men and women. All participants will undergo muscle mass assessments via D3-Cr, body composition (LST, aLST, fat mass) via DXA, and dietary intake by 24h recall (ASA24) at baseline, 1y and 2y of follow-up. Performance-based assessments of physical function, mobility status and muscular strength will also be conducted at baseline, 1y and 2y of follow-up. During the quarterly follow-up phone calls, all participants will be screened limitation screening questions (see inclusion criteria), allowing us to capture changes in mobility status (i.e., no, early, minor or major mobility limitation) over time.
A fixed dose titration (with doses ranging from 10mg to 40mg/day) will be used. Subjects will take 10mg/day for 1 week, 20mg/day for 1 week and then 40mg/day.
Cardiac hypertrophy (CH) is one of the stages in the occurrence and development of severe cardiovascular diseases, and exploring its biomarkers is beneficial for delaying the progression of severe cardiovascular diseases. In this research, we established a comprehensive and highly efficient pseudotargeted metabolomics method, which demonstrated a superior capacity to identify differential metabolites when compared to traditionaluntargeted metabolomics. The intra/inter-day precision and reproducibility results proved the method is reliable and precise. The established method was then applied to seek the potential differentiated metabolic biomarkers of cardiac hypertrophy (CH) rats, and oxylipins, phosphorylcholine (PC), lysophosphatidylcholine (LysoPC), lysophosphatidylethanolamine (LysoPE), Krebs cycle intermediates, carnitines, amino acids, and bile acids were disclosed to be the possible differentiate components. Their metabolic pathway analysis revealed that the potential metabolic alterations in CH rats were mainly associated with phenylalanine, tyrosine and tryptophan biosynthesis, phenylalanine metabolism, arachidonic acid metabolism, citrate cycle, glyoxylate and dicarboxylate metabolism, and tyrosine metabolism. In sum, this research provided a comprehensiveand reliable LC-MS/MS MRM platform for pseudo-targeted metabolomics investigation of disease condition, and some interesting potential biomarkers were disclosed for CH, which merit further exploration in the future.
Daikenchuto (TJ-100), a traditional Japanese herbal medicine, is used for prevention and treatment of postoperative ileus. TJ-100 extract powder (Tsumura \& Co., Tokyo, Japan) is manufactured as an aqueous extract containing 2.2 % Japanese pepper, 5.6 % processed ginger, 3.3 % ginseng, and 88.9 % maltose syrup powder. A recent randomized, parallel-group, double-blind, placebo-controlled, dose-response trial demonstrated that TJ-100 accelerates colonic transit time, particularly in the ascending colon. Given its potential actions in the intestinal tract, it seems reasonable to postulate that TJ-100 may play a role in improving and preventing bowel dysmotility. This study was designed to investigate the effect of TJ-100 on intestinal dysmotility and for the prevention of postoperative paralytic ileus in patients undergoing pancreaticoduodenectomy.

The primary endpoint is the incidence of postoperative paralytic ileus. Secondary endpoints are QOL assessment by the Gastrointestinal Symptom Rating Scale (GSRS) Score (Japanese Version) and visual analogue scale, the change in ratio of abdominal circumference, the incidence of postoperative complications, the length of hospital day, and the incidence of surgical site infection. Two hundred patients are required for the study (100 patients per group).
Diabetic nephropathy (DN) is the leading cause of end-stage renal disease globally. Currently, there are no effective drugs for the treatment of DN. Although several studies have reported the therapeutic potential of mesenchymal stem cells, the underlying mechanisms remain largely unknown. Here, we report that both human umbilical cord MSCs (UC-MSCs) and UC-MSC-derived exosomes (UC-MSC-exo) attenuate kidney damage, and inhibit epithelial-mesenchymal transition (EMT) and renal fibrosis in streptozotocin-induced DN rats. Strikingly, the Hedgehog receptor, smoothened (SMO), was significantly upregulated in the kidney tissues of DN patients and rats, and positively correlated with EMT and renal fibrosis. UC-MSC and UC-MSC-exo treatment resulted in decrease of SMO expression. In vitro co-culture experiments revealed that UC-MSC-exo reduced EMT of tubular epithelial cells through inhibiting Hedgehog/SMO pathway. Collectively, UC-MSCs inhibit EMT and renal fibrosis by delivering exosomes and targeting Hedgehog/SMO signaling, suggesting that UC-MSCs and their exosomes are novel anti-fibrotic therapeutics for treating DN.